# A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

> **NCT00517699** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 5 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** Methotrexate
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00517699
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated early due to lack of enrollment.
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517699, "A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00517699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*